Literature DB >> 18058083

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients.

G Targher1, L Bertolini, S Rodella, G Zoppini, G Lippi, C Day, M Muggeo.   

Abstract

AIMS/HYPOTHESIS: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular disease in type 2 diabetes. Currently, there is a lack of information on associations between NAFLD and microvascular complications of diabetes. We assessed the associations between NAFLD and both chronic kidney disease (CKD) and retinopathy in a large cohort of type 2 diabetic individuals using a cross-sectional design.
METHODS: Prevalence rates of retinopathy (by ophthalmoscopy) and CKD (defined as overt proteinuria and/or estimated GFR <or= 60 ml min(-1) 1.73 m(-2)) were assessed in 2,103 type 2 diabetic individuals who were free of diagnosed cardiovascular disease and viral hepatitis. NAFLD was ascertained by patient history, blood sampling and liver ultrasound.
RESULTS: NAFLD patients had higher (p<0.001) age- and sex-adjusted prevalence rates of both non-proliferative (39 vs 34%) and proliferative/laser-treated retinopathy (11 vs 5%), and CKD (15 vs 9%) than counterparts without NAFLD. In logistic regression analysis, NAFLD was associated with increased rates of CKD (odds ratio 1.87; 95% CI 1.3-4.1, p=0.020) and proliferative/laser-treated retinopathy (odds ratio 1.75; 1.1-3.7, p=0.031) independently of age, sex, BMI, waist circumference, hypertension, diabetes duration, HbA(1c), lipids, smoking status and medications use. CONCLUSIONS/
INTERPRETATION: Our findings suggest that NAFLD is associated with an increased prevalence of CKD and proliferative/laser-treated retinopathy in type 2 diabetic individuals independently of numerous baseline confounding factors. Further studies are required to confirm the reproducibility of these results and to evaluate whether NAFLD contributes to the development or progression of CKD and retinopathy.

Entities:  

Mesh:

Year:  2007        PMID: 18058083     DOI: 10.1007/s00125-007-0897-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  36 in total

1.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

Review 2.  Non-alcoholic fatty liver disease: current concepts and management strategies.

Authors:  Chris P Day
Journal:  Clin Med (Lond)       Date:  2006 Jan-Feb       Impact factor: 2.659

3.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

Review 4.  Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications.

Authors:  Pantelis A Sarafidis; Luis M Ruilope
Journal:  Am J Nephrol       Date:  2006-05-29       Impact factor: 3.754

5.  Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients.

Authors:  A Y S Cheng; A P S Kong; V W S Wong; W Y So; H L Y Chan; C S Ho; C W K Lam; J S Tam; C C Chow; C S Cockram; J C N Chan; P C Y Tong
Journal:  Diabetologia       Date:  2006-05-31       Impact factor: 10.122

Review 6.  Nonalcoholic fatty liver disease and the metabolic syndrome.

Authors:  Giulio Marchesini; Rebecca Marzocchi; Federica Agostini; Elisabetta Bugianesi
Journal:  Curr Opin Lipidol       Date:  2005-08       Impact factor: 4.776

7.  Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis.

Authors:  E Albano; E Mottaran; M Vidali; E Reale; S Saksena; G Occhino; A D Burt; C P Day
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

8.  Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Stefano Rodella; Guido Arcaro; Christopher Day
Journal:  J Hepatol       Date:  2007-02-15       Impact factor: 25.083

9.  Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.

Authors:  Marie-Christine Alessi; Delphine Bastelica; Alenka Mavri; Pierre Morange; Bruno Berthet; Michel Grino; Irene Juhan-Vague
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-15       Impact factor: 8.311

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  104 in total

1.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

Review 2.  Roles of liver innate immune cells in nonalcoholic fatty liver disease.

Authors:  Yu-Tao Zhan; Wei An
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

3.  Mediterranean diet in type 2 diabetes.

Authors:  F J Basterra-Gortari; M A Martínez-González
Journal:  Diabetologia       Date:  2008-08-19       Impact factor: 10.122

Review 4.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

5.  Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate.

Authors:  Daniela Catalano; Guglielmo M Trovato; Giuseppe Fabio Martines; Clara Pirri; Francesca M Trovato
Journal:  Hepatol Int       Date:  2011-01-28       Impact factor: 6.047

Review 6.  Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.

Authors:  Raseen Tariq; Page Axley; Ashwani K Singal
Journal:  J Clin Exp Hepatol       Date:  2019-07-25

7.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.

Authors:  G Targher; L Bertolini; M Chonchol; S Rodella; G Zoppini; G Lippi; L Zenari; E Bonora
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

8.  Association of Diabetic Nephropathy and Liver Disorders.

Authors:  Usha Sachidananda Adiga; B N Malawadi
Journal:  J Clin Diagn Res       Date:  2016-10-01

9.  Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis.

Authors:  Robert M Wilechansky; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Liver Int       Date:  2019-05-24       Impact factor: 5.828

10.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.